Leerink Partners analyst Mike Kratky maintained a Buy rating on AxoGen (AXGN – Research Report) on November 25 and set a price target of $0.00.

Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it ...

Eagle Asset Management Inc. bought a new stake in AxoGen, Inc. (NASDAQ:AXGN – Free Report) in the third quarter, according to ...

The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with ...

Patient age, level of injury, mechanism of injury, and associated medical conditions all influence outcome and, in certain cases, may make repair or grafting unreasonable. Conceptually ...

all synergistic and independent movements are possible S0 Absence of sensibility in the autonomous area S1 Recovery of deep cutaneous pain sensibility within the autonomous area of the nerve S2 ...

nerve grafting, and tendon transfers. Access to integrative medicine and supportive therapy. Comprehensive care in collaboration with the patient's primary care provider and referring physician.

When the researchers analyzed the graft itself, it appeared that regular exercise stimulated the grafted muscle to produce ...